Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
60.26
-0.84 (-1.37%)
Mar 20, 2026, 3:00 PM CST
SHA:688621 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | - | 565.56 | 690.93 | 608.93 | 490.25 |
Short-Term Investments | - | 20 | - | - | - |
Trading Asset Securities | - | 30 | 30 | 13.11 | 157.6 |
Cash & Short-Term Investments | 706.41 | 615.56 | 720.93 | 622.04 | 647.85 |
Cash Growth | 14.76% | -14.62% | 15.90% | -3.98% | 492.70% |
Accounts Receivable | - | 774.96 | 555.83 | 362.73 | 239.2 |
Other Receivables | - | 10.16 | 11.21 | 16.17 | 12 |
Receivables | - | 785.12 | 567.04 | 378.9 | 251.21 |
Inventory | - | 15.05 | 14.41 | 12.54 | 7.84 |
Prepaid Expenses | - | - | - | - | 1.9 |
Other Current Assets | - | 98.76 | 54.76 | 26.48 | 32.99 |
Total Current Assets | - | 1,514 | 1,357 | 1,040 | 941.79 |
Property, Plant & Equipment | - | 211.61 | 220.26 | 197.02 | 161.05 |
Long-Term Investments | - | 115.69 | 100.75 | 94.75 | 40 |
Goodwill | - | 26.06 | 26.06 | 26.06 | 26.06 |
Other Intangible Assets | - | 5.41 | 5.39 | 4.2 | 3.32 |
Long-Term Deferred Tax Assets | - | 64.04 | 38.93 | 16.69 | 5.03 |
Long-Term Deferred Charges | - | 48.28 | 64.19 | 76.25 | 33.41 |
Other Long-Term Assets | - | 1.73 | 50.31 | 8.78 | 31.99 |
Total Assets | - | 1,987 | 1,863 | 1,464 | 1,243 |
Accounts Payable | - | 7.31 | 7.83 | 22.13 | 12.52 |
Accrued Expenses | - | 77.24 | 88.72 | 37.29 | 27.33 |
Short-Term Debt | - | 309.39 | 383.93 | 201.17 | 138.01 |
Current Portion of Long-Term Debt | - | 19.3 | - | - | - |
Current Portion of Leases | - | 24.78 | 22.1 | 22.54 | 18.98 |
Current Income Taxes Payable | - | 6.6 | 24.92 | 16.93 | 11.42 |
Current Unearned Revenue | - | 321.43 | 220.83 | 205.85 | 199.85 |
Other Current Liabilities | - | 12.51 | 12.88 | 12.27 | 9.72 |
Total Current Liabilities | - | 778.56 | 761.21 | 518.19 | 417.83 |
Long-Term Debt | - | 67.2 | - | - | - |
Long-Term Leases | - | 35.12 | 40.62 | 33.84 | 49.72 |
Long-Term Unearned Revenue | - | 2.52 | 3.59 | 2.83 | 5.46 |
Long-Term Deferred Tax Liabilities | - | 1.25 | 0.35 | 0.24 | - |
Total Liabilities | - | 884.65 | 805.76 | 555.1 | 473.01 |
Common Stock | - | 112 | 112 | 80 | 80 |
Additional Paid-In Capital | - | 375.86 | 474.17 | 499.85 | 499.85 |
Retained Earnings | - | 612.78 | 453.85 | 317.09 | 182.1 |
Total Common Equity | 1,162 | 1,101 | 1,040 | 896.93 | 761.95 |
Minority Interest | - | 2.01 | 17.25 | 11.67 | 7.69 |
Shareholders' Equity | 1,165 | 1,103 | 1,057 | 908.6 | 769.64 |
Total Liabilities & Equity | - | 1,987 | 1,863 | 1,464 | 1,243 |
Total Debt | 588.42 | 455.79 | 446.65 | 257.55 | 206.71 |
Net Cash (Debt) | 117.99 | 159.77 | 274.28 | 364.48 | 441.14 |
Net Cash Growth | -26.15% | -41.75% | -24.75% | -17.38% | 414.12% |
Net Cash Per Share | 1.08 | 1.42 | 2.45 | 3.26 | 4.50 |
Filing Date Shares Outstanding | 109.41 | 112 | 112 | 112 | 112 |
Total Common Shares Outstanding | 109.28 | 112 | 112 | 112 | 112 |
Working Capital | - | 735.93 | 595.93 | 521.77 | 523.96 |
Book Value Per Share | 10.64 | 9.83 | 9.29 | 8.01 | 6.80 |
Tangible Book Value | 1,132 | 1,069 | 1,009 | 866.68 | 732.57 |
Tangible Book Value Per Share | 10.36 | 9.55 | 9.01 | 7.74 | 6.54 |
Machinery | - | 256.34 | 232.62 | 195.9 | 124.14 |
Construction In Progress | - | - | - | - | 3.4 |
Order Backlog | - | 3,273 | - | - | - |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.